2 Biotechnology Companies with Small Market Capitalization That Could Provide Returns for Long-Term Investors

Small-cap biotech stocks such as Mainz Biomed and NanoViricides present significant risks, but they also offer the potential for substantial returns as their diagnostic and antiviral pipelines evolve.

Mainz Biomed: Early Cancer Detection with Potential for Growth

Mainz Biomed AG (NASDAQ: MYNZ) is a German company specializing in molecular diagnostics, focusing on epigenetic tests for early cancer detection. Unlike many small biotech firms, Mainz Biomed already has a product on the market: ColoAlert, the first DNA-based screening test for colorectal cancer in Europe.

In early December, Mainz Biomed announced that ColoAlert had been added to the portfolio of DoctorBox, a leading digital health company in Germany. With over 60,000 new colorectal cancer cases reported annually in Germany, this development opens up significant market opportunities for the company.

Additionally, Mainz Biomed is working on a blood-based test for the early detection of pancreatic cancer. The company recently reported promising results, though this product is still in the early stages of development and is years away from commercial approval.

Despite this progress, Mainz Biomed faces challenges. ColoAlert is not yet available in the United States, and its revenues remain limited, even with its presence in Europe and plans to expand into South America. As a result, the company has faced financial pressure, with its September SEC filing including a "Going Concern" warning. In response, Mainz Biomed filed a $150 million mixed shelf offering to secure the capital it needs to stay afloat and avoid delisting. While the risks are significant, successful product development could lead to notable returns for investors.

NanoViricides: High-Risk Antiviral Technology with Promising Potential

NanoViricides Inc. (NYSE: NNVC) is another small biotech company with a high-risk, high-reward profile. The company is developing a unique class of antiviral treatments using its proprietary nanoviricide platform, which mimics human cell surfaces to attract viruses and neutralize them before they can infect real cells.

Its current pipeline includes antiviral candidates targeting shingles (varicella-zoster virus), herpes simplex viruses (HSV-1 and HSV-2), and influenza. The most advanced of these is the NV-HSC program, aimed at treating shingles, which has shown promising preclinical results suggesting strong antiviral activity.

However, like many small-cap biotechs, NanoViricides is not yet generating revenue and remains dependent on external funding to continue its development. Recent filings have shown limited cash reserves, and there is a risk of dilution if the company needs to raise more capital. Despite these financial challenges, the potential for significant upside remains if NanoViricides' antiviral candidates succeed in clinical trials. For investors willing to take on substantial risk, NNVC stock offers the chance for substantial rewards in the antiviral space.

Both Mainz Biomed and NanoViricides present compelling investment opportunities for those with a high risk tolerance and a long-term investment horizon. However, investors should be prepared for volatility, and the path to profitability for both companies remains uncertain.

Sources:

• 2 Small-Cap Biotechs That Could Reward Patient Investors